Zai Lab (Shanghai) Co., Ltd.
Clinical trials sponsored by Zai Lab (Shanghai) Co., Ltd., explained in plain language.
A commercial-stage biopharmaceutical company developing and commercializing medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- First human test of ZL-1503 begins to uncover how the body handles it Results expected Feb 2027 (estimated)
- New hope for thyroid eye disease: phase 3 drug trial launches in china Results expected Mar 2027 (estimated)
- New drug cocktail targets tough lung cancer Results expected May 2027 (estimated)
- New drug ZL-1310 tested in patients with Hard-to-Treat cancers Results expected Aug 2027 (estimated)
- Can a new drug ease schizophrenia symptoms in daily life? Results expected Aug 2027 (estimated)
-
New hope for tough lung cancer: targeted drug ZL-1310 enters final testing
Disease control Recruiting nowThis Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…
Phase 3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail targets tough lung cancer
Disease control Recruiting nowThis study tests a new drug called ZL-1310, alone or with standard treatments (atezolizumab and carboplatin), in people with small cell lung cancer. About 339 participants will join to see if the combination is safe and shrinks tumors. The goal is to find better ways to control t…
Phase 1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New drug ZL-1310 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called ZL-1310 in adults with advanced neuroendocrine carcinomas (a type of solid tumor) that have worsened after platinum-based chemotherapy. The trial has two parts: Phase 1b checks safety and side effects, while Phase 2 looks at whether the drug shr…
Phase 1/2 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New eczema drug ZL-1503 enters first human safety trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called ZL-1503 for safety and how the body processes it. It involves 84 participants: first healthy volunteers, then people with moderate to severe atopic dermatitis (eczema). The study is 'double-blind' and 'placebo-controlled,' meani…
Phase 1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cancer drug ZL-6201 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called ZL-6201 in adults with sarcoma or certain solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. About 180 people will take part in this study.
Phase 1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC